MedPath

Comparison of Intra-operative Radiotherapy With Post-operative Radiotherapy for Women With Early Breast Cancer

Phase 3
Completed
Conditions
Breast Cancer
Invasive Breast Cancer
Interventions
Device: Intrabeam
Radiation: Post-operative radiotherapy
Registration Number
NCT00983684
Lead Sponsor
University College, London
Brief Summary

The purpose of this study is to evaluate whether a single fraction of radiotherapy given intra-operatively and targeted to the tissues at the highest risk of local recurrence is equivalent to standard post-operative external beam radiotherapy after breast conserving surgery in women with early stage breast cancer in terms of local relapse within the treated breast.

Detailed Description

TARGIT is an international randomised clinical trial designed to test the hypothesis that the strategy of delivering a single dose of targeted intraoperative radiotherapy (IORT) in patients eligible for breast conserving therapy (with the addition of whole breast radiotherapy in those patients at high risk of recurrence elsewhere in the breast \[e.g. lobular carcinomas and extensive intraductal component\]) is equivalent to a conventional course of post-operative external beam radiotherapy (EBRT). The primary endpoints are local and loco-regional recurrence rates. It is a pragmatic trial in which each participating centre has the option to define more restrictive entry criteria than in the core protocol. Only centres with access to the Intrabeam® (Carl Zeiss) enter patients into the trial. Eligible patients are those with tumours of good prognosis suitable for breast conserving surgery. After giving consent patients are randomised to either IORT or to EBRT. They may receive any other adjuvant treatments as deemed necessary, except for neoadjuvant therapy. The protocol requires that patients be followed at six monthly intervals for five years and then annually.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
3451
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Intra-operative radiotherapyIntrabeamA single fraction of radiotherapy given intra-operatively and targeted to the tissues at the highest risk of local recurrence.
Post-operative radiotherapyPost-operative radiotherapyStandard post-operative radiotherapy.
Primary Outcome Measures
NameTimeMethod
Local relapse within the treated breast.3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 72, 84, 96, 108, 120 months
Secondary Outcome Measures
NameTimeMethod
Site of relapse within the breast3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 72, 84, 96, 108, 120 months
Relapse-free survival and overall survival3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 72, 84, 96, 108, 120 months
Local toxicity/morbidity3, 6, 12, 18, 24, 30, 36, 42, 48, 54, 60, 72, 84, 96, 108, 120 months

Trial Locations

Locations (1)

Clinical Trials Group

🇬🇧

London, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath